期刊文献+

Immune Regulation of Interleukin-27 in Malignant Pleural Effusion 被引量:4

Immune Regulation of Interleukin-27 in Malignant Pleural Effusion
原文传递
导出
摘要 Background: lnterlcukin (IL)-27 has been reported to have anti-proliferate and anti-angiogenic activities on cancer cells. However, the involvement of IL-27 in malignant pleural effusion (MPE) remains unknown. Thus, in this research, we compared the immune functions of IL-27, interferon (IFN)-γ, and IL-17 on lung cancer cells and revealed the regulatory mechanism of IL-27 in MPE. Methods: The distribution ofl L-27 in both MPE and blood was evaluated by enzyme-linked immunosorbent assay and flow cytometry. The expressions otcytokine receptors and the levels of the phosphorylated signal transducer and activator of transcription (STAT) signalings were detected by flow cytometry. As well as the effects of proliferation, apoptosis, migration, and adherent activity of IL-27, IFN-γ, and IL-17 on lung cancer cells were also explored. Results: The expression of IL-27 was increased in M PE when compared with blood ( 147.3 ± 25. 1 pg/ml vs. 100.3 ± 13.9 pg/ml, P = 0.04). IL-27 was noted to suppress both proliferation (18.33 ±0.21 vs. 27.77 ±0.88, P = 0.0005) and migration (1.82 ±0.44 vs. 3.13 ±0.07, P = 0.04) of A549 cells, but obviously prornoted apoptosis of A549 cells (9.47 ±1.14 vs. 4.96 ±0.17, P = 0.02) by activating STAT1 signaling. Interestingly, IL-27 played totally opposite effects on A549 cells by activating STAT3 pathway. Moreover, IL-27 exerted different intercellular adherent activities ofA549 cells to pleural mesothelial cell monolayer by activating different STAT signalings. Conelusions: IL-27 might exert an important immune regulation on lung cancer cells in human pleural malignant environment. Background: lnterlcukin (IL)-27 has been reported to have anti-proliferate and anti-angiogenic activities on cancer cells. However, the involvement of IL-27 in malignant pleural effusion (MPE) remains unknown. Thus, in this research, we compared the immune functions of IL-27, interferon (IFN)-γ, and IL-17 on lung cancer cells and revealed the regulatory mechanism of IL-27 in MPE. Methods: The distribution ofl L-27 in both MPE and blood was evaluated by enzyme-linked immunosorbent assay and flow cytometry. The expressions otcytokine receptors and the levels of the phosphorylated signal transducer and activator of transcription (STAT) signalings were detected by flow cytometry. As well as the effects of proliferation, apoptosis, migration, and adherent activity of IL-27, IFN-γ, and IL-17 on lung cancer cells were also explored. Results: The expression of IL-27 was increased in M PE when compared with blood ( 147.3 ± 25. 1 pg/ml vs. 100.3 ± 13.9 pg/ml, P = 0.04). IL-27 was noted to suppress both proliferation (18.33 ±0.21 vs. 27.77 ±0.88, P = 0.0005) and migration (1.82 ±0.44 vs. 3.13 ±0.07, P = 0.04) of A549 cells, but obviously prornoted apoptosis of A549 cells (9.47 ±1.14 vs. 4.96 ±0.17, P = 0.02) by activating STAT1 signaling. Interestingly, IL-27 played totally opposite effects on A549 cells by activating STAT3 pathway. Moreover, IL-27 exerted different intercellular adherent activities ofA549 cells to pleural mesothelial cell monolayer by activating different STAT signalings. Conelusions: IL-27 might exert an important immune regulation on lung cancer cells in human pleural malignant environment.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2015年第14期1932-1941,共10页 中华医学杂志(英文版)
基金 Source of Support: This work was supported by grants in part from National Basic Research Program of China (No. 2012CB518706) in part from National Natural Science Foundation of China (No. 81272591 and No. 81470274). Conflict of Interest: None declared.
关键词 INTERLEUKIN-27 Lung Cancer Malignant Pleural Effusion Signal Transduction Interleukin-27 Lung Cancer Malignant Pleural Effusion Signal Transduction
  • 相关文献

参考文献30

  • 1Stathopoulos GT, Kalomenidis 1. Malignant pleural effusion: Tumor-host interactions unleashed. Am J Respir Crit Care Med 2012; 186:487-92.
  • 2Marazioti A, Blackwell TS, Stathopoulos GT. The lymphatic system in malignant pleural effusion. Drain or immune switch? Am J Respir Crit Care Med 2014;189:626-7.
  • 3Marazioti A, Stathopoulos GT. Monoclonal antibody targeting of mononuclear cell chemokines driving malignant pleural effusion. Oncoimmunology 2014;3:e29195.
  • 4Roberts ME, Neville E, Berrisford RG, Antunes G, All N J, BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Coociety Pleural Disease Guideline 2010. Thorax 2010;65 Suppl 2:ii32-40.
  • 5Thomas JM, Musani AI. Malignant pleural effusions: A review. Clin Chest Med 2013;34:459-71.
  • 6Nam HS. Malignant pleural effilsion: Medical approaches for diagnosis and management. Tuberc Respir Dis (Seoul) 2014;76:211-7.
  • 7Maskell NA. Treatment options for malignant pleural effusions: Patient preference does matter. JAMA 2012:307:2432-3.
  • 8Murugaiyan G, Saha B. IL-27 in tumor immunity and immunotherapy. Trends Mol Med 2013;19:108-16.
  • 9Pflanz S, Yirnans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 2002; 16:779-90.
  • 10Pflanz S, Hibbcrt L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX- 1 and glycoprotein 130 constitute a signal-transdt,cing receptor for IL-27. J lmmunol 2004;172:2225-31.

同被引文献32

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部